on Nanohale AG (ETR:FYB)
Formycon AG Holds Annual General Meeting 2026
Formycon AG recently concluded its Annual General Meeting (AGM) for 2026 in Munich. The Management Board provided a thorough review of the company's performance in 2025 and discussed its future strategy. Shareholders approved all agenda items with large majorities. The meeting highlighted significant progress in Formycon's biosimilar pipeline and solidified its financial foundation for growth.
The "FYB4Growth" strategy remains central, integrating geographic diversification, a comprehensive portfolio approach, and cost efficiency. A profit and loss transfer agreement was approved, aiming to optimize internal tax benefits. 62.34% of the company's share capital participated in the vote.
Detailed voting results can be found on the Formycon website. The company aims to continue its development as a profitable biosimilar leader in the industry.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Nanohale AG news